Myelodysplastic Syndromes

180

Pipeline Programs↗

52

Active Trials↗

72

Companies Involved↗

Myelodysplastic Syndromes is a highly competitive landscape with 180 programs across 72 companies. The most active players are AbbVie, Nuwacell Biotechnologies Co., Ltd., Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 5 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

39/100

Mech. Concentration

5/100

Completion Rate

64/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

AbbVie

2 programs

Nuwacell Biotechnologies Co., Ltd.

2 programs

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

Taiho Oncology, Inc.

2 programs

Mirati Therapeutics Inc.

1 program

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical8

Pravastatin Sodium

Teva

FLAG Induction

University of Florida

Low-Dose Cytarabine

Bristol-Myers Squibb

Biological Data

University Hospital, Bordeaux

Erythropoiesis-Stimulating Agents

Bristol-Myers Squibb

Phase 136

Atezolizumab

Roche

Melphalan

Apotex Inc.

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Venetoclax

AbbVie

Bevacizumab

Bio-Thera Solutions

Phase 2111

Nivolumab

Bristol-Myers Squibb

Dexamethasone

Aspen Global Incorporated

Cyclophosphamide

Baxter Healthcare Corporation

Methotrexate

Alnylam Pharmaceuticals

Daratumumab

Johnson & Johnson

Phase 320

Thalidomide

Bristol-Myers Squibb

Thioguanine

Akero Therapeutics

Etoposide

Avyxa

Filgrastim

Eastern Cooperative Oncology Group

Eltrombopag

GSK

Approved5

Imetelstat

Geron Corporation

Idarubicin

Pfizer

G-CSF

Arog Pharmaceuticals, Inc.

EXJADE

Assistance Publique - Hôpitaux de Paris

Cytarabine

Teva

Analysis

Modality Breakdown

87%

Small molecule

173 of 200 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 200 classified programs, each share of the total. Modality classified for 99% of 208 pipeline programs.

Analysis

Trial Status

245

clinical trials

Completed112 · 46%

Terminated50 · 20%

Recruiting27 · 11%

Active, not recruiting18 · 7%

Unknown status17 · 7%

Withdrawn12 · 5%

Other9 · 4%

Clinical Trials

Trial Activity

245 trials

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05925504·36 enrolled

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Recruiting·UUniversity of Manitoba·Phase 2·NCT06599762·75 enrolled

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Recruiting·GGluBio Therapeutics Inc.·Phase 1·NCT06146257·48 enrolled

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Recruiting·RRemedy Plan, Inc.·Phase 1·NCT07107126·24 enrolled

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT06465953·48 enrolled

Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)

Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT05924074·80 enrolled

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Recruiting·GGroupe Francophone des Myelodysplasies·Phase 1·NCT06670222·24 enrolled

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06484062·54 enrolled

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Recruiting·—·Phase 2·NCT07047183·46 enrolled

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

Recruiting·PPharmacosmos A/S·Phase 2·NCT05693909·90 enrolled

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Recruiting· Takeda logo

Takeda·Phase 2·NCT04419649·160 enrolled

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT03816319·42 enrolled

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

Recruiting·WWashington University School of Medicine·Phase 2·NCT05483010·16 enrolled

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Recruiting·AAkeso·Phase 2·NCT06196203·90 enrolled

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·SSawa Ito, MD·Phase 2·NCT06529731·45 enrolled

Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)